#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 visits (enrollment open)
#

Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker

Description

The study is a global, multicenter, randomized, double-blind, active-controlled, parallel-group study to evaluate the comparative efficacy, safety, immunogenicity, and interchangeability of ADL-018 with US-Xolair® administered subcutaneously (SC) as an add-on therapy for the treatment of adult patients aged 18 to 75 who have been diagnosed with refractory CIU and who remain symptomatic despite standarddosed H1 antihistamine treatment. The study will consist of 4 distinct study periods over a time period of 42 weeks.

Is this not what you are looking for?
Check out our other studies.

Related Studies

#

Chronic Idiopathic Urticaria

  • Compensation to be determined
  • 13 clinic visits including 3 safety follow-up visits
#
Between 18 - 75 Years

#
Male or Female
#
Smoker & Non-Smoker
#

Small Cell Lung Cancer

  • Compensation to be determined
  • Clinical visits 24
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
#

Ulcerative Colitis (IQVIA)

  • Compensation to be determined
  • clinic visits 10
#
18+ Years

#
Male or Female
#
Smoker & Non-Smoker
© 2024 Access Research Institute. All Rights Reserved